Original Publication Date: 1 September, 2014
Publication / Source: Pharmacogenomics
Authors: Nicola Silvestris, Bruno Vincenzi, Anna Elisabetta Brunetti et al
Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology.